---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-279630"
form_type: "8-K/A"
ticker: "SGMO"
cik: "0001001233"
company_name: "SANGAMO THERAPEUTICS, INC"
filed_at: "2026-06-23T20:42:16+00:00"
generated_at: "2026-06-23T20:43:25.728985+00:00"
event_type: "m_and_a"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Sangamo files Ch 11, sells key capsid/gene therapy assets to Eli Lilly and Astellas

## Summary
- Sangamo filed Chapter 11 bankruptcy and signed asset sale agreements with Eli Lilly and Astellas Gene Therapies.
- Lilly's subsidiary is stalking horse bidder for capsids (STAC-150, STAC-BBB), SIFTER, MINT, and zinc finger prion assets.
- Astellas acquires assets under separate agreement; terms not disclosed in this filing.
- Sangamo common stock delisted from Nasdaq on May 5, 2026; now trading on OTCQB.
- Sale subject to Bankruptcy Court approval and potential higher bids in auction process.

## SEC filing metadata
- accession: 0001193125-26-279630
- form_type: 8-K/A
- ticker: SGMO
- cik: 0001001233
- company_name: SANGAMO THERAPEUTICS, INC
- filed_at: 2026-06-23T20:42:16+00:00
- event_type: m_and_a
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001233/000119312526279630/0001193125-26-279630-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001233/000119312526279630/d68888d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-279630
- JSON: https://secwatch.observer/filing/0001193125-26-279630.json
- Plain text: https://secwatch.observer/filing/0001193125-26-279630.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.